However, we did not observe a clear trend of modulation of these markers, and we think this could be due to the limited sample and heterogeneous patient populations from the early phase I study (Figure S4B , S4C ).
← all excerpts
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
1
—
—